Alto Neuroscience, Inc. Faces Class Action Lawsuit Over Alleged Misleading Statements

Strategic Insights -

Alto Neuroscience, Inc.'s initial public offering (IPO) in February 2024 was touted as a promising step forward in the treatment of major depressive disorder (MDD), with its flagship candidate, ALTO-100, set to undergo a Phase 2b clinical trial. However, a class action lawsuit filed on behalf of investors alleges that the company's statements about the efficacy and potential of ALTO-100 were intentionally misleading. On October 22, 2024, Alto released topline results from the Phase 2b trial, which showed that ALTO-100 did not meet its primary endpoint, leading to a drastic decline in the company's stock price.

Key Takeaways:

  • The class action lawsuit alleges that Alto Neuroscience, Inc. made negligent and intentional misrepresentations about the viability of its drug candidate, ALTO-100, in support of its initial public offering (IPO).
  • The complaint claims that during the class period, defendants failed to disclose that ALTO-100 was less effective in treating MDD than defendants had led investors to believe.
  • On October 22, 2024, Alto issued a press release announcing topline results from the Phase 2b trial, which stated that ALTO-100 did not meet its primary endpoint.
  • The stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
  • Shareholders who purchased Alto securities between February 2, 2024, and October 22, 2024, may be eligible to participate in the class action lawsuit.
  • The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Statistics:

  • On October 23, 2024, Alto's stock price closed at $4.36 per share, down $10.17 per share, or 69.99% from the previous day's close.
  • The class period covers from February 2, 2024, to October 22, 2024.
  • The litigation is ongoing, and shareholders who want to serve as lead plaintiff for the class have until September 19, 2025, to seek lead plaintiff status from the court.

Sources:

  • "Alto Neuroscience, Inc. Subsidiary (ANRO) Aware: Securities Class Action Filed" PRNewswire
  • "Alto Neuroscience, Inc. (ANRO) Reminds Shareholders with Class Action Lawsuit as Deadline Approaches" PRNewswire